99 results about "Depressive symptoms" patented technology

The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.

The invention discloses an aromatic essential oil drug for preventing and treating depression, boosting mood and improving brain function and its composition, which contains main pharmacological active ingredients: vanillin, vanillin salt or isomers of vanillin Any one, two or three mixtures can also be added with other natural spices and native plant essential oils such as rosewood, clove, benzoin essential oils and so on. The medicine of the present invention stimulates the olfactory nerve through the nose and the oral cavity to regulate the olfactory center of the brain and then affect different brain regions, so as to improve brain function, relieve depression, improve mood, and reduce suicide rate, and has quick onset, low concentration, no toxic side effect.

The invention provides a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand for use in the treatment of symptoms of anxiety and/or depression associated with an affective disorder and/or symptoms associated with cognitive impairment disorder. Particularly useful are diphenhydramine derivatives of Formula (I) and particularly (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin) (Captodiamine).

Disclosed is a method for screening patients to determine whether or not SSRI therapy is likely to alleviate symptoms of depression in those patients. The method provides a polymorphism at position −1019 of the 5-HT1A gene that is predictive of likelihood of improvement of symptoms and a polymorphism at position 102 of the 5-HT2A gene that is predictive of likelihood of unwanted side effects related to SSRI therapy administered to a patient.

The invention relates to metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for producing a medicament used for treating depression, and related methods of treating depression.

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

The invention relates to an E-mental symptom fast screening and self-checking system for assisting diagnosis and treatment. The system comprises an initial interface, a scale selecting interface, a scale assessing interface and a detecting result interface. The scale selecting interface comprises four selectable scales including a QIDS-SR 16, an HCL-32, an MDQ and a PHQ-9, and the four scales are self-rating depression scales. The detecting result interface comprises grades, condition description, clinic prompt and an instruction. By means of the testing result, a patient can be guided to pertinently see a doctor, and the doctor can be assisted to carry out the diagnosis and treatment. The system can serve as a screening tool for bipolar disorder and other diseases and can also serve as a tool for monitoring the illness. The tablet personal computer technology serves as the basis, the system is simple in structure, and operation is easy and convenient due to the fact that input is achieved through a touch screen and a computer keyboard.

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

The invention provides a Chinese medicine composition to achieve the purpose of treating depression through clearing heat, eliminating phlegm, promoting blood circulation, removing blood stasis, soothing liver, regulating qi, restoring consciousness, improving the blood circulation, quickly improving depressive symptoms, and effectively controlling depressive illnesses. In order to achieve the purpose, the following technical scheme is adopted: active components contained in the Chinese medicine composition are prepared by the following raw materials in parts by weight: 6-12 parts of orange peel, 4-8 parts of rhizoma pinellinae praeparata, 3-6 parts of poria cocos, 4-8 parts of bamboo shavings, 4-8 parts of fruit of immature citron, 2-4 parts of ginger, 4-8 parts of lily, 4-8 parts of rehmannia, 4-8 parts of rhizoma anemarrhenae, 3-6 parts of radix glycyrrhizae preparata and 2-4 parts of jujubes; and a corresponding preparation method is adopted. The Chinese medicine composition has the function of treating depression.

The invention belongs to the technical field of beverage processing and relates to a healthcare fruit and vegetable composite beverage. The healthcare fruit and vegetable composite beverage is made from snow pear juice, watermelon juice, aloe juice, Maca juice, okra juice, banana juice and honey. Various fresh fruit and vegetable raw materials are squeezed through a physical method to obtain liquid juice, and the liquid juice is scientifically mixed into the beverage. The beverage is comfortable in taste, has the effects of quenching thirst and soothing the nerves, and can relieve depressive symptoms; the formula is scientific and reasonable, no toxic or side effect exists, the preparation process is simple and mature, the intended population range is wide, the retention cycle is long, the taste is good, and rich nutrients are obtained.

The invention discloses a special chocolate for astronauts and a production method thereof. The chocolate is prepared from the following raw materials: a cocoa butter replacer, cocoa powder, whole milk powder, whey protein, phospholipid, a white peony root extract, a citron extract, a fingered citron extract, a largehead atractylodes rhizome extract, a perilla leaf extract, a banana extract, a perilla stem extract, a pericarpium citri reticulatae viride extract, an elecampane extract, a fructus aurantii extract, a radix curcumae extract, a bamboo shavings extract, a bamboo juice extract, an eupatorium extract, a fructus amomi extract, a cortex magnolia officinalis extract, an amomum tsao-ko extract, a rosemary extract and a mung bean hull extract. The traditional Chinese medicine compound chocolate provided by the invention is scientific and reasonable in matching of the raw materials, low in cost, convenient to take and high in safety, and can be used for effectively alleviating the psychological stress and depressive symptoms of the astronauts, so that the astronauts throw themselves into glorious and holyare aerospace business with full enthusiasm.

The invention relates to the field of medicine, in particular to a polypeptide capable of simulating the brain-derived-neurotrophic-factor physiological function and reducing depressive symptoms. The sequence is SEQ ID NO:1, and the SEQ ID NO:1 is a bran-new sequence. The polypeptide has the advantages that the BDNF content of chronic inscrutable stress model rat brain tissue can be increased. The in-vivo pharmacological result shows that depressive symptoms of acute and chronic depression model animals can be improved through the polypeptide, and the polypeptide can serve as an effective candidate treating method for clinical depression.

The invention relates to music intense pulsed light auditory meatus depression therapeutic equipment, in particular a music modulated intense pulsed light auditory meatus depression therapeutic equipment. The intensity or/and color of the light-emitting diode (LED) color-change auditory meatus light is modulated or not modulated according to the amplitude of music synchronous with the heart rate, the light is used for irradiating auditory meatus most close to the brain, and bright light is directly transmitted to a photosensitive area of the brain to activate the brain function, improve the secretion of a neurotransmitter and effectively relieve depression depressive symptoms; meanwhile, an LED color-change lighting lamp irradiates a human body and skin, passes through retina, and acts on the brain to improve the therapeutic effect of irradiation; and by combining speed-change music listening, music current, electric field therapy and transcranial music magnetic stimulation therapy, the equipment realizes omnibearing therapy synchronous with the heart rate to fulfill the aim of treating depression.

Disclosed is a new application of a bisbenzylisoquinoline derivative shown in formula (I) in the specification or pharmaceutically acceptable salt thereof. The application is an application of the bisbenzylisoquinoline derivative shown in formula (I) or the pharmaceutically acceptable salt thereof in preparing medicines or health care products for curing depression and easing depression symptom. The bisbenzylisoquinoline derivative shown in formula (I) or the pharmaceutically acceptable salt thereof can be taken as an effective component to prepare a drug type of any form. A result of an animal experiment shows that, the bisbenzylisoquinoline compound shown in formula (I) or the pharmaceutically acceptable salt thereof can obviously shorten immobility time of a mouse in a forced swimming test and immobility time of the mouse in a tail suspending test, which shows an anti-depression function. The present invention is applicable to various types of depression.

The invention relates to the field of medicine, and discloses a novel application of 3-methoxyl mangiferin in the field of pharmacy, and a medicine composition comprising 3-methoxyl mangiferin. 3-methoxyl mangiferin can promote hippocampus dentate gyrus neuron 5-hydroxytryptamine 1A receptor gene and protein expressions, and can induce neurotrophic effects such as hippocampus remodeling performed by 5-hydroxytryptamine. Therefore, post-stroke hippocampus nerve aregeneratory can be substantially ameliorated, 5-HT re-uptake of nerve presynaptic membrane can be selectively inhibited, 5-HT positive cell expression at hypothalamus can be reduced, exhaustion of 5-HT can be relieved, and anxiety and depression symptoms caused by 5-HT exhaustion can be relieved. Therefore, 3-methoxyl mangiferin can be used in preparing medicines used for treating post-stroke depression.

The invention relates to a soft capsule for preventing and treating Alzheimer's disease and a preparation method of the soft capsule. The soft capsule is prepared from the following raw materials in parts by weight: 60 to 80 parts of acer truncatum bunge seed oil, 10 to 25 parts of phospholipid, 6 to 8 parts of seville orange flower, 4 to 7 parts of lycium ruthenicum, and pharmaceutical excipients for the soft capsule. According to the capsule, a large amount of acetylcholine can be generated in a body, the content of the acetylcholine in a brain of an Alzheimer's disease patient is increased, and information conduction is enhanced, so as to activate brain cells and improve memory and intelligence level. The capsule contains natural nervonic acid; the nervonic acid is a unique chemical substance which is recognized in the present world and can be used for repairing damaged nerve fibers, and can promote repair and regeneration of the damaged nerve fibers, thereby improving the memory and the intelligence level. Meanwhile, the soft capsule also has the effects of improving the activity of NK cells and enhancing cellular immunity and humoral immunity, thereby improving human immune functions. The seville orange flower has the efficacy of activating Qi and easing middle jiao, and regulating Qi and soothing the liver, thereby relieving depressive symptoms of the Alzheimer's disease patient.

The invention relates to a liquid chromatography method for effectively separating and analyzing agomelatine and synthetic intermediates as well as impurities. The agomelatine is a melatonin excitant, has a depressive symptom resistance effect and can improve the night sleeping condition under the condition without influencing the daytime activity state. The invention aims at providing the efficient liquid chromatogram method for separating the agomelatine and the synthetic intermediates as well as the impurities. A octadecyl silane bonding silica gel filling chromatographic column is adopted so that a flowing phase A (organic phase) and a flowing phase B (water phase) prepared from buffer solution (with the pH being 6 to 7) and organic solvents according to different proportions are used as flowing phases, the flowing rte is 1.0ml/min, the gradient elution is carried out, and the separation and the analysis determination of the agomelatine and the synthetic intermediates as well as the impurities are realized.

The invention discloses application of Clostridium butyricum in the preparation of preparations for preventing or treating depression, and particularly relates to the application of the Clostridium butyricum in depression preventing or treating and depressive symptom relieving.

The invention discloses application of all-cannabinoid in preparation of drugs for treating depression. The all-cannabinoid is prepared by uniformly mixing, by weight, 0.3-99.7 parts of an industrial hemp seed extract with 99.7-0.3 parts of industrial cannabinoids. The all-cannabinoid has the obvious relieving effect on the symptoms such as secondary learning memory deterioration of the depression and can be used for preparing the drugs for treating various depression symptoms including endogenous depression, reactive depression, latent depression, secondary depression caused by drugs, climacteric or postnatal depression, depression induced by cerebral trauma or stroke, diabetes-complicated depression and depressive neurosis and used for preparing the drugs for treating the symptoms such as secondary learning memory deterioration and anhedonia which are caused by the depression, and the effect of the all-cannabinoid is better than that of cannabidiol. The all-cannabinoid can be prepared into the clinical drugs of various dosage forms through a conventional preparation method and is convenient to use.

The invention relates inter alia to methods for predicting the response of patients with depressive symptoms and/or anxiety symptoms to treatment with a CRHR1 antagonist, and algorithms, kits, microarrays, probes and or/primers for use in such methods.

A composition having an activity of ameliorating the reduced amount of diurnal activity and/or depressive symptoms, comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid.

The invention discloses an anti-depression light-wave instrument and application thereof. The anti-depression light-wave instrument comprises a switch part, a control part and a light source part, wherein the switch part is connected with an adjusting part by the control part; the adjusting part is connected with the light source part; the adjusting part is used for providing 2.3-2.9V of voltage for the light source part; the light emitted by a light source is monochromatic light in visible light. The better wavelength range is 590-630nm of orange light. The invention also discloses the light source of the anti-depression light-wave instrument. The anti-depression light-wave instrument can be used for resisting depression and anxiety. According to the invention, the depressive symptoms are improved and the side effects of pharmaceutical drugs for resisting depression are reduced.